ArticleDiabetology & metabolic syndrome2025
Effects of sodium-glucose co-transporter-2 inhibitors on the risk of nephrolithiasis and urinary tract infections in Thai patients with type 2 diabetes: a hospital-based cohort study.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sodium-glucose cotransporter 2 inhibitorsTranslational andrology and urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNephrolithiasis is a multifactorial disease with many contributing factors varying across races, ethnicities, and sociocultural backgrounds. Diabetes is a significant independent risk factor for nephrolithiasis. We aimed to investigate the association between sodium-glucose co-transporter-2 inhibitors (SGLT2is) and the risk of nephrolithiasis in Thai patients with type 2 diabetes (T2D).
methodsThis retrospective cohort study of T2D patients used real-world data from Ramathibodi Hospital, Bangkok, Thailand. Adult T2D patients aged 18 years or older who had received SGLT2is, dipeptidyl peptidase 4 inhibitors (DPP4is), sulfonylureas (SUs), or thiazolidinediones (TZDs) were included. Inverse probability weighting with regression adjustment and Cox proportional hazards models were applied to estimate the effect of SGLT2is on the risk of nephrolithiasis as the primary outcome, and on the risk of urinary tract infections (UTIs) as a secondary outcome.
resultsA total of 17,821 patients were identified between 2015 and 2023, of whom 5,626 received an SGLT2i. The median follow-up time was 1.8 years. The incidence rate of nephrolithiasis was 7.7, 18.5, 20.5, and 12.1 per 1000 person-years in the SGLT2i, DPP4i, SU, and TZD groups, respectively. The risk of nephrolithiasis was significantly lower for patients who had received SGLT2is compared to those who had received DPP4is (HR = 0.45; 95% CI: 0.35, 0.58), SUs (HR = 0.37; 95% CI: 0.28, 0.48), and TZDs (HR = 0.60; 95% CI: 0.43, 0.85). The risk of UTIs appeared lower with SGLT2is compared to DPP4is (HR = 0.85; 95% CI: 0.66, 1.10) and TZDs (HR = 0.78; 95% CI: 0.55, 1.11), with a statistically significant reduction observed only relative to SUs (HR = 0.74; 95% CI: 0.56, 0.96).
conclusionsOur real-world study suggested a lower risk of nephrolithiasis in Thai T2D patients treated with SGLT2is, without any increase in UTIs. These real-world findings identify added benefit for T2D patients prescribed SGLT2is for nephrolithiasis prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.